Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Advanced Melanoma × pembrolizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 115 Parkinson Disease 4, Autosomal Dominant Lewy Body 103 Melanoma 71 Squamous Cell Carcinoma of Head and Neck 44 Neoplasms 37 Colorectal Neoplasms 33 Breast Neoplasms 32 Stomach Neoplasms 31 Triple Negative Breast Neoplasms 30 Neoplasm Metastasis 28 Ovarian Neoplasms 27 Head and Neck Neoplasms 26 Urinary Bladder Neoplasms 25 Lung Neoplasms 25 Carcinoma, Renal Cell 24 Carcinoma, Transitional Cell 21 Carcinoma, Hepatocellular 20 Esophageal Neoplasms 19 Pancreatic Neoplasms 18 Fallopian Tube Neoplasms 14 Endometrial Neoplasms 14 Prostatic Neoplasms 13 Multiple Myeloma 13 Recurrence 12 Lymphoma, Follicular 12 Carcinoma 12 Sarcoma 11 Lymphoma, Large B-Cell, Diffuse 11 Carcinoma, Squamous Cell 11 Glioblastoma 10

Interventions

pembrolizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03407170 2020-07-15

KEYNOTE-161

Merck Sharp & Dohme LLC

Phase 2 Terminated

1 enrolled 3 charts

Advanced Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡